These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37253281)

  • 21. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.
    Prohaska TA; Alexander VJ; Karwatowska-Prokopczuk E; Tami J; Xia S; Witztum JL; Tsimikas S
    J Clin Lipidol; 2023; 17(3):406-411. PubMed ID: 37164837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
    Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL
    J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen.
    Isaac RH; Gonzalez-Devia D; Mendivil CO; Chapman E
    Front Allergy; 2023; 4():1201807. PubMed ID: 37361109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome-Causes, Clinical Presentation, and Therapeutic Options.
    Bashir B; Ho JH; Downie P; Hamilton P; Ferns G; Datta D; Cegla J; Wierzbicki AS; Dawson C; Jenkinson F; Delaney H; Mansfield M; Teoh Y; Miedzybrodzka Z; Haso H; Durrington PN; Soran H
    Metabolites; 2023 Apr; 13(5):. PubMed ID: 37233662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of therapies for chylomicronemia.
    Shamsudeen I; Hegele RA
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):395-405. PubMed ID: 35762447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome.
    Paquette M; Amyot J; Fantino M; Baass A; Bernard S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3473-e3482. PubMed ID: 34019660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-prandial analysis of fluctuations in the platelet count and platelet function in patients with the familial chylomicronemia syndrome.
    Larouche M; Brisson D; Morissette MC; Gaudet D
    Orphanet J Rare Dis; 2023 Jun; 18(1):167. PubMed ID: 37370069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials.
    Calcaterra I; Lupoli R; Di Minno A; Di Minno MND
    Eur J Clin Invest; 2022 Nov; 52(11):e13841. PubMed ID: 35851450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.
    Hegele RA; Berberich AJ; Ban MR; Wang J; Digenio A; Alexander VJ; D'Erasmo L; Arca M; Jones A; Bruckert E; Stroes ES; Bergeron J; Civeira F; Witztum JL; Gaudet D
    J Clin Lipidol; 2018; 12(4):920-927.e4. PubMed ID: 29748148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome: Focus on Volnesorsen.
    Gesner M; Frishman WH
    Cardiol Rev; 2023 Nov-Dec 01; 31(6):325-329. PubMed ID: 36129324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symptoms and impacts of familial chylomicronemia syndrome: a qualitative study of the patient experience.
    Williams K; Tickler G; Valdivielso P; Alonso J; Vera-Llonch M; Cubells L; Acaster S
    Orphanet J Rare Dis; 2023 Oct; 18(1):316. PubMed ID: 37817256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.
    Meyers CD; Tremblay K; Amer A; Chen J; Jiang L; Gaudet D
    Lipids Health Dis; 2015 Feb; 14():8. PubMed ID: 25889044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides.
    Gouni-Berthold I
    J Endocr Soc; 2020 Feb; 4(2):bvz035. PubMed ID: 32083235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The burden of familial chylomicronemia syndrome in Canadian patients.
    Gaudet D; Stevenson M; Komari N; Trentin G; Crowson C; Hadker N; Bernard S
    Lipids Health Dis; 2020 Jun; 19(1):120. PubMed ID: 32487261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.
    Oral EA; Garg A; Tami J; Huang EA; O'Dea LSL; Schmidt H; Tiulpakov A; Mertens A; Alexander VJ; Watts L; Hurh E; Witztum JL; Geary RS; Tsimikas S
    J Clin Lipidol; 2022; 16(6):833-849. PubMed ID: 36402670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Treatment of Lipoprotein Lipase Deficiency with Medium-Chain Triglyceride-Enriched Diet: A Case Series.
    Aljouda L; Nagy L; Schulze A
    Nutrients; 2023 Aug; 15(16):. PubMed ID: 37630727
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe hypertriglyceridaemia as a result of familial chylomicronaemia: the Cape Town experience.
    Pouwels ED; Blom DJ; Firth JC; Henderson HE; Marais AD
    S Afr Med J; 2008 Feb; 98(2):105-8. PubMed ID: 18350203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the chylomicron-TG to VLDL-TG ratio for type I hyperlipoproteinemia diagnostic.
    Rioja J; Ariza MJ; García-Casares N; Coca-Prieto I; Arrobas T; Muñiz-Grijalvo O; Mangas A; Ibarretxe D; Sánchez-Chaparro MÁ; Valdivielso P
    Eur J Clin Invest; 2020 Dec; 50(12):e13345. PubMed ID: 32649781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
    Stroes ESG; Alexander VJ; Karwatowska-Prokopczuk E; Hegele RA; Arca M; Ballantyne CM; Soran H; Prohaska TA; Xia S; Ginsberg HN; Witztum JL; Tsimikas S;
    N Engl J Med; 2024 May; 390(19):1781-1792. PubMed ID: 38587247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS).
    Bashir B; Kwok S; Wierzbicki AS; Jones A; Dawson C; Downie P; Jenkinson F; Delaney H; Mansfield M; Datta D; Teoh Y; Hamilton P; Forrester N; O'Sullivan D; Ferdousi M; Durrington PN; AbdelRazik A; Gallo A; Moulin P; Soran H
    Atherosclerosis; 2024 Apr; 391():117476. PubMed ID: 38447437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.